[ 1 ] Kumar R, Gautam G, Gupta NP. Drug therapy for idiopathic male infertility: rationale versus evidence. J Urol 2006;176(4):1307–12. link1

[ 2 ] Kumar N, Singh AK. Trends of male factor infertility, an important cause of infertility: a review of literature. J Hum Reprod Sci 2015;8(4):191–6. link1

[ 3 ] Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, et al.; European Association of Urology Working Group on Male Infertility. European Association of Urology guidelines on male infertility: the 2012 update. Eur Urol 2012;62(2):324–32.

[ 4 ] Duca Y, Calogero AE, Cannarella R, Condorelli RA, La Vignera S. Current and emerging medical therapeutic agents for idiopathic male infertility. Expert Opin Pharmacother 2019;20(1):55–67. link1

[ 5 ] Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M. Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology 2013;1(5):749–57. link1

[ 6 ] Ebisch IM, Thomas CM, Peters WH, Braat DD, Steegers-Theunissen RP. The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility. Hum Reprod Update 2007;13(2):163–74. link1

[ 7 ] Agarwal A, Said TM. Carnitines and male infertility. Reprod Biomed Online 2004;8(4):376–84. link1

[ 8 ] Shang XJ, Wang LL, Mo DS, Cai HC, Zheng DD, Zhou YZ. Effect and safety of Lcarnitine in the treatment of idiopathic oligoasthenozoospermia: a systemic review. Natl J Androl 2015;21(1):65–73. link1

[ 9 ] Arcaniolo D, Favilla V, Tiscione D, Pisano F, Bozzini G, Creta M, et al. Is there a place for nutritional supplements in the treatment of idiopathic male infertility? Arch Ital Urol Androl 2014;86(3):164. link1

[10] Omar MI, Pal RP, Kelly BD, Bruins HM, Yuan Y, Diemer T, et al. Benefits of empiric nutritional and medical therapy for semen parameters and pregnancy and live birth rates in couples with idiopathic infertility: a systematic review and meta-analysis. Eur Urol 2019;75(4):615–25. link1

[11] Lafuente R, González-Comadrán M, Solà I, López G, Brassesco M, Carreras R, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet 2013;30(9):1147–56. link1

[12] Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013;346:f2914.

[13] Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147.

[14] Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23(20):3105–24. link1

[15] Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14(4):417–28. link1

[16] Salanti G. Indirect and mixed-treatment comparison, network, or multipletreatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012;3 (2):80–97. link1

[17] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162(11):777. link1

[18] www.who.int [Internet]. Geneva: World Health Organization; [cited 2021 Jul 8]. Available from: https://apps.who.int/iris/bitstream/handle/10665/44261/ 9789750011245_tur.pdf. link1

[19] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al.; Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[20] Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT, Tu YK. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE 2014;9(7):e99682. link1

[21] Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G, Haibe-Kains B. Graphical tools for network meta-analysis in STATA. PLoS ONE 2013;8(10): e76654. link1

[22] Chaimani A, Salanti G. Visualizing assumptions and results in network metaanalysis: the network graphs package. Stata J 2015;15(4):905–50. link1

[23] Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol 2013;42(1):332–45. link1

[24] Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64(2):163–71. link1

[25] Gregoriou O, Papadias C, Gargaropoulos A, Konidaris S, Kontogeorgi Z, Kalampokas E. Treatment of idiopathic infertility with testosterone undecanoate. A double blind study. Clin Exp Obstet Gynecol 1993;20 (1):9–12. link1

[26] Adamopoulos DA, Nicopoulou S, Kapolla N, Karamertzanis M, Andreou E. The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril 1997;67(4):756–62. link1

[27] Matsumiya K, Kitamura M, Kishikawa H, Kondoh N, Fujiwara Y, Namiki M, et al. A prospective comparative trial of a gonadotropin-releasing hormone analogue with clomiphene citrate for the treatment of oligoasthenozoospermia. Int J Urol 1998;5(4):361–3. link1

[28] Foresta C, Bettella A, Merico M, Garolla A, Ferlin A, Rossato M. Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. Fertil Steril 2002;77(2):238–44. link1

[29] Wong WY, Merkus HM, Thomas CM, Menkveld R, Zielhuis GA. Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2002;77(3):491–8. link1

[30] Wang YX, Zhai CB, Yang SW, Cai WQ, Cai GZ, Yin XL. Tamoxifen treat idiopathic oligozoospermia: a clinical trial. Clin Med Chin 2002;18(7):658–9. Chinese. link1

[31] Selice R, Garolla A, Pengo M, Caretta N, Ferlin A, Foresta C. The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. Int J Androl 2011;34(4 pt 1):306–12.

[32] Farrag A, Sagnella F, Pappalardo S, Costantini A, Lisi F, Carfagna P, et al. The use of r-hFSH in treatment of idiopathic male factor infertility before ICSI. Eur Rev Med Pharmacol Sci 2015;19(12):2162–7. link1

[33] Sharifzadeh F, Norouzi S, Ashrafi M, Aminimoghaddam S, Koohpayezadeh J. Effects of zinc sulfate on subfertility related to male factors: a prospective double-blind, randomized, placebo-controlled clinical trial. J Obstet Gynaecol 2016;1(2):e7242.

[34] Zhao N, Lu XL, Li JT, Zhang JM. Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: a randomised, double-blinded, placebo-controlled clinical study. Andrologia 2019;51(6):e13271. link1

[35] Scott R, MacPherson A, Yates RW, Hussain B, Dixon J. The effect of oral selenium supplementation on human sperm motility. Br J Urol 1998;82 (1):76–80. link1

[36] Adamopoulos DA, Pappa A, Billa E, Nicopoulou S, Koukkou E, Michopoulos J. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 2003;80 (4):914–20. link1

[37] Balercia G, Buldreghini E, Vignini A, Tiano L, Paggi F, Amoroso S, et al. Coenzyme Q10 treatment in infertile men with idiopathic asthenozoospermia: a placebo-controlled, double-blind randomized trial. Fertil Steril 2009;91(5):1785–92. link1

[38] Wang YX, Yang SW, Qu CB, Huo HX, Li W, Li JD, et al. L-carnitine: safe and effective for asthenozoospermia. Natl J Androl 2010;16(5):420–2. link1

[39] Haghighian HK, Haidari F, Mohammadi-Asl J, Dadfar M. Randomized, tripleblind, placebo-controlled clinical trial examining the effects of a-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertil Steril 2015;104(2):318–24. link1

[40] Balercia G, Regoli F, Armeni T, Koverech A, Mantero F, Boscaro M. Placebocontrolled double-blind randomized trial on the use of L-carnitine, Lacetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005;84(3):662–71. link1

[41] Alahmar AT, Sengupta P. Impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in men with idiopathic infertility. Biol Trace Elem Res 2021;199(4):1246–52. link1

[42] Rowe PJ; the World Health Organization, Task force on the Prevention and Management of Infertility and Frank Comhaire. A double-blind trial of clomiphene citrate for the treatment of idiopathic male infertility. Int J Androl 1992;15(4):299–307. link1

[43] Krause W, Holland-Moritz H, Schramm P. Treatment of idiopathic oligozoospermia with tamoxifen—a randomized controlled study. Int J Androl 1992;15(1):14–8. link1

[44] Crottaz B, Senn A, Reymond MJ, Rey F, Germond M, Gomez F. Folliclestimulating hormone bioactivity in idiopathic normogonadotropic oligoasthenozoospermia: double-blind trial with gonadotropin-releasing hormone. Fertil Steril 1992;57(5):1034–43. link1

[45] Kotoulas IG, Cardamakis E, Michopoulos J, Mitropoulos D, Dounis A. Tamoxifen treatment in male infertility. I. Effect on spermatozoa. Fertil Steril 1994;61(5):911–4. link1

[46] Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L, Dondero F, et al. Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial. Fertil Steril 2003;79(2):292–300. link1

[47] Lenzi A, Sgrò P, Salacone P, Paoli D, Gilio B, Lombardo F, et al. A placebocontrolled double-blind randomized trial of the use of combined L-carnitine and L-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004;81(6):1578–84. link1

[48] Li Z, Chen GW, Shang XJ, Bai WJ, Han YF, Chen B, et al. A controlled randomized trial of the use of combined L-carnitine and acetyl-L-carnitine treatment in men with oligoasthenozoospermia. Chin J Androl 2005;11 (10):761–4. Chinese. link1

[49] Sigman M, Glass S, Campagnone J, Pryor JL. Carnitine for the treatment of idiopathic asthenospermia: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2006;85(5):1409–14. link1

[50] Paradisi R, Busacchi P, Seracchioli R, Porcu E, Venturoli S. Effects of high doses of recombinant human follicle-stimulating hormone in the treatment of male factor infertility: results of a pilot study. Fertil Steril 2006;86(3):728–31. link1

[51] He XY, Li G, Zhang X, Jiang H, Zhao LM, Dai DX, et al. Clinical study of a small dose of androgen for the treatment of oligoasthenospermatism. Chin J Androl 2009;23(12):42–5. Chinese. link1

[52] Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril 2010;93(7):2232–5. link1

[53] Moradi M, Moradi A, Alemi M, Ahmadnia H, Abdi H, Ahmadi A, et al. Safety and efficacy of clomiphene citrate and L-carnitine in idiopathic male infertility: a comparative study. Urol J 2010;7(3):188–93. link1

[54] Tang KF, Xing Y, Wu CY, Liu RZ, Wang XY, Xing JP. Tamoxifen combined with coenzyme Q10 for idiopathic oligoasthenospermia. Chin J Androl 2011;17 (7):615–8. Chinese. link1

[55] Zhong A, Tang L, Tang L, Zheng H, Liu H. The clinical research on treating idiopathi oligospermia or asthenospermia patients with the combination of L-carnitine, vitamin E and C. J Pract Med 2012;28 (23):3997–9. Chinese. link1

[56] Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol 2012;188(2):526–31. link1

[57] Paradisi R, Natali F, Fabbri R, Battaglia C, Seracchioli R, Venturoli S. Evidence for a stimulatory role of high doses of recombinant human folliclestimulating hormone in the treatment of male-factor infertility. Andrologia 2014;46(9):1067–72. link1

[58] ElSheikh MG, Hosny MB, Elshenoufy A, Elghamrawi H, Fayad A, Abdelrahman S. Combination of vitamin E and clomiphene citrate in treating patients with idiopathic oligoasthenozoospermia: a prospective, randomized trial. Andrology 2015;3(5):864–7. link1

[59] Ding YM, Zhang XJ, Li JP, Chen SS, Zhang RT, Tan WL, et al. Treatment of idiopathic oligozoospermia with recombinant human follicle-stimulating hormone: a prospective, randomized, double-blind, placebo-controlled clinical study in Chinese population. Clin Endocrinol 2015;83(6):866–71. link1

[60] Yin J, Chen X, Wang Y. Curative effect of tamoxifen combined with pancreatic kallikrein on patients of oligoasthenospermia. Chin J Hum Sexuality 2014;23 (11):17–9. Chinese. link1

[61] Guo L, Jing J, Feng YM, Yao B. Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia. Int Urol Nephrol 2015;47(9):1463–9. link1

[62] Martinez AM, Sordia-Hernández LH, Morales JA, Merino M, Vidal O, Garza MRG, et al. A randomized clinical study assessing the effects of the antioxidants, resveratrol or SG1002, a hydrogen sulfide prodrug, on idiopathic oligoasthenozoospermia. Asian Pac J Reprod 2015;4(2):106–11. link1

[63] Haje M, Naoom K. Combined tamoxifen and L-carnitine therapies for the treatment of idiopathic male infertility attending intracytoplasmic sperm injection: a randomized controlled trial. Int J Infertil Fetal Med 2015;6 (1):20–4. link1

[64] Tsounapi P, Honda M, Dimitriadis F, Koukos S, Hikita K, Zachariou A, et al. Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: a randomised controlled trial. Andrologia 2018;50 (8):e13071. link1

[65] Cheng JB, Zhu J, Ni F, Jiang H. L-carnitine combined with coenzyme Q10 for idiopathic oligoasthenozoospermia: a double-blind randomized controlled trial. Chin J Androl 2018;24(1):33–8. Chinese. link1

[66] Gerris J, Comhaire F, Hellemans P, Peeters K, Schoonjans F. Placebo-controlled trial of high-dose mesterolone treatment of idiopathic male infertility. Fertil Steril 1991;55(3):603–7. link1

[67] Keck C, Behre HM, Jockenhövel F, Nieschlag E. Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebocontrolled trial. Hum Reprod 1994;9(2):325–9. link1

[68] Kamischke A, Behre HM, Bergmann M, Simoni M, Schafer T, Nieschlag E. Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. Hum Reprod 1998;13(3):596–603. link1

[69] Caroppo E, Niederberger C, Vizziello GM, D’Amato G. Recombinant human follicle-stimulating hormone as a pretreatment for idiopathic oligoasthenoteratozoospermic patients undergoing intracytoplasmic sperm injection. Fertil Steril 2003;80(6):1398–403. link1

[70] Baccetti B, Piomboni P, Bruni E, Capitani S, Gambera L, Moretti E, et al. Effect of follicle-stimulating hormone on sperm quality and pregnancy rate. Asian J Androl 2004;6(2):133–7. link1

[71] Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. Fertil Steril 2005;84 (3):654–61. link1

[72] Çakan M, Aldemir M, Topcuoglu M, Altug˘ U. Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men. Urol Int 2009;83(4):446–51. link1

[73] Ciftci H, Verit A, Savas M, Yeni E, Erel O. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology 2009;74(1):73–6. link1

[74] Safarinejad MR, Safarinejad S. Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo controlled, randomized study. J Urol 2009;181(2):741–51. link1

[75] Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 2009;182 (1):237–48. link1

[76] Safarinejad MR. Effect of pentoxifylline on semen parameters, reproductive hormones, and seminal plasma antioxidant capacity in men with idiopathic infertility: a randomized double-blind placebo-controlled study. Int Urol Nephrol 2011;43(2):315–28. link1

[77] Safarinejad MR. Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic anti-oxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratospermia: a double-blind, placebo-controlled, randomised study. Andrologia 2011;43 (1):38–47. link1

[78] Nadjarzadeh A, Sadeghi MR, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Coenzyme Q10 improves seminal oxidative defense but does not affect on semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind, placebo controlled trial. J Endocrinol Invest 2011;34(8):e224–8. link1

[79] Chen XF, Li Z, Ping P, Dai JC, Zhang FB, Shang XJ. Efficacy of natural vitamin E on oligospermia and asthenospermia: a prospective multi-centered randomized controlled study of 106 cases. Natl J Androl 2012;18(5):428–31. link1

[80] Da Silva TM, Maia MCS, Arruda JT, Approbato FC, Mendonça CR, Approbato MS. Folic acid does not improve semen parametrs in subfertile men: a double-blin, randomized, placebo-controlled study. JBRA Assist Reprod 2013;17(3):152–7. link1

[81] Jia T, Zhang B, Liang M, Zhao L, Yang H, Sun W. Effect of FSH on the treatment of patients with idiopathic oligospermia and asthenospermia. Chin J Hum Sexuality 2013;22(3):7–9. Chinese. link1

[82] Moslemi Mehni N, Ketabchi AA, Hosseini E. Combination effect of pentoxifylline and L-carnitine on idiopathic oligoasthenoteratozoospermia. Iran J Reprod Med 2014;12(12):817–24. link1

[83] Nadjarzadeh A, Shidfar F, Amirjannati N, Vafa MR, Motevalian SA, Gohari MR, et al. Effect of coenzyme Q10 supplementation on antioxidant enzymes activity and oxidative stress of seminal plasma: a double-blind randomised clinical trial. Andrologia 2014;46(2):177–83. link1

[84] Helli B, Kavianpour M, Ghaedi E, Dadfar M, Haghighian HK. Probiotic effects on sperm parameters, oxidative stress index, inflammatory factors and sex hormones in infertile men. Hum Fertil. In press.

[85] Alkumait MHMS, Abdul-Aziz MM, Nima MH. The effect of glutathione versus co-enzyme Q10 on male infertility original study. Med Leg Update 2020;20 (1):409–14. link1

[86] Kumalic SI, Klun IV, Bokal EV, Pinter B. Effect of the oral intake of astaxanthin on semen parameters in patients with oligo-astheno-teratozoospermia: a randomized double-blind placebo-controlled trial. Radiol Oncol 2020;55 (1):97–105. link1

[87] Eslamian G, Amirjannati N, Noori N, Sadeghi MR, Hekmatdoost A. Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial. Am J Clin Nutr 2020;112(3):707–19. link1

[88] Amini L, Mohammadbeigi R, Vafa M, Haghani H, Vahedian-Azimi A, Karimi L, et al. Evaluation of the effect of vitamin D3 supplementation on quantitative and qualitative parameters of spermograms and hormones in infertile men: a randomized controlled trial. Complement Ther Med 2020;53:102529. link1

[89] Bahmyari R, Ariafar A, Sayadi M, Hossieni S, Azima S. The effect of daily intake of selenium, vitamin E and folic acid on sperm parameters in males with idiopathic infertility: a single-blind randomized controlled clinical trial. Int J Fertil Steril 2021;15(1):8–14. link1

[90] Attia AM, Abou-Setta AM, Al-Inany HG. Gonadotrophins for idiopathic male factor subfertility. Cochrane Database Syst Rev 2013;(8):CD005071.

[91] Santi D, Granata AR, Simoni M. FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis. Endocr Connect 2015;4(3): R46–58. link1

[92] Nagvenkar P, Zaveri K, Hinduja I. Comparison of the sperm aneuploidy rate in severe oligozoospermic and oligozoospermic men and its relation to intracytoplasmic sperm injection outcome. Fertil Steril 2005;84(4):925–31. link1

[93] Simoni M, Santi D. FSH treatment of male idiopathic infertility: time for a paradigm change. Andrology 2020;8(3):535–44. link1

[94] Valenti D, Vignera SL, Condorelli RA, Rago R, Barone N, Vicari E, et al. Folliclestimulating hormone treatment in normogonadotropic infertile men. Nat Rev Urol 2013;10(1):55–62. link1

[95] Cannarella R, La Vignera S, Condorelli RA, Mongioì LM, Calogero AE. FSH dosage effect on conventional sperm parameters: a meta-analysis of randomized controlled studies. Asian J Androl 2020;22(3):309–16. link1

[96] Chehab M, Madala A, Trussell JC. On-label and off-label drugs used in the treatment of male infertility. Fertil Steril 2015;103(3):595–604. link1

[97] Cannarella R, Condorelli RA, Mongioì LM, Barbagallo F, Calogero AE, La Vignera S. Effects of the selective estrogen receptor modulators for the treatment of male infertility: a systematic review and meta-analysis. Expert Opin Pharmacol 2019;20(12):1517–25. link1

[98] Alleva R, Scararmucci A, Mantero F, Bompadre S, Leoni L, Littarru GP. The protective role of ubiquinol-10 against formation of lipid hydroperoxides in human seminal fluid. Mol Aspects Med 1997;18(Suppl):221–8. link1

[99] Gvozdjáková A, Kucharská J, Dubravicky J, Mojto V, Singh RB. Coenzyme Q10, a-tocopherol, and oxidative stress could be important metabolic biomarkers of male infertility. Dis Markers 2015;2015:1–6. link1

[100] Gharagozloo P, Aitken RJ. The role of sperm oxidative stress in male infertility and the significance of oral antioxidant therapy. Hum Reprod 2011;26 (7):1628–40. link1

[101] Agarwal A, Sekhon LH. The role of antioxidant therapy in the treatment of male infertility. Hum Fertil 2010;13(4):217–25. link1

[102] Buhling K, Schumacher A, zu Eulenburg C, Laakmann E. Influence of oral vitamin and mineral supplementation on male infertility: a meta-analysis and systematic review. Reprod BioMed Online 2019;39(2):269–79. link1

[103] Ross C, Morriss A, Khairy M, Khalaf Y, Braude P, Coomarasamy A, et al. A systematic review of the effect of oral antioxidants on male infertility. Reprod BioMed Online 2010;20(6):711–23. link1

[104] Showell MG, Mackenzie-Proctor R, Brown J, Yazdani A, Stankiewicz MT, Hart RJ. Antioxidants for male subfertility. Cochrane Database Syst Rev 2014;(12): CD007411.

[105] Alahmar AT. The effects of oral antioxidants on the semen of men with idiopathic oligoasthenoteratozoospermia. Clin Exp Reprod Med 2018;45 (2):57–66. link1

[106] Mills JN, Yao DF. Male infertility: lifestyle factors and holistic, complementary, and alternative therapies. Asian J Androl 2016;18(3):410–8. link1

[107] Li J, Wu XK, Zhang JX. Acupuncture treatment of oligoasthenozoospermia. Natl J Androl 2018;24(1):86–90. link1

[108] Ter Veer E, van Oijen MGH, van Laarhoven HWM. The use of (network) metaanalysis in clinical oncology. Front Oncol 2019;9:822. link1

[109] Mongioi L, Calogero AE, Vicari E, Condorelli RA, Russo GI, Privitera S, et al. The role of carnitine in male infertility. Andrology 2016;4(5):800–7. link1

[110] Legro RS, Wu X, Barnhart KT, Farquhar C, Fauser BC, Mol B, et al.; Harbin Consensus Conference Workshop Group, Conference Chairs, Scientific Committee. Improving the reporting of clinical trials of infertility treatments (IMPRINT): modifying the CONSORT statement. Hum Reprod 2014;29(10):2075–82.

[111] Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10(1):28–55. link1